Metacognitive Intervention in Youth With Oncological Disease - the Mio Study
Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jun 12, 2024
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The Mio Study is a clinical trial designed to help teenagers with cancer by improving their thinking skills and physical abilities during and after treatment. Researchers want to see how effective a special app, called the Mio-App, can be in helping these young patients develop better awareness of their own thinking (this is called metacognition) and improve their cognitive and physical performance. The app will include fun exercises and questions to help track their progress. This study aims to understand how different factors, such as age, gender, and fatigue, can influence the success of the training program.
To participate in the Mio Study, young people aged 10 to 16 who are currently receiving cancer treatment or have just finished treatment may qualify. They should be able to speak either German or French. However, those with certain neurological conditions, severe psychiatric issues, or who may have trouble following the study's procedures won't be eligible. Participants can expect to engage with the app and take part in activities that could help their recovery and development over time. This trial is an exciting opportunity to explore new ways to support adolescents facing the challenges of cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent as documented by signature (see Informed Consent Form) of participants and / or parents / legal guardians
- • Age 10-16 years
- • A diagnosis of cancer either with or without central nervous system (CNS) involvement
- • Treatment of cancer including either radiation, chemotherapy and/ or surgical tumor removal
- • Three months before to three months after the end of cancer treatment
- • German or French speaking
- Exclusion Criteria:
- • Any other instable neurological condition (e.g. epilepsy)
- • A severe psychiatric disease (e.g., eating disorder) or severe learning disability
- • Known or suspected non-compliance
- • Drug or alcohol abuse
- • Inability to follow the procedures of the study, e.g. due to language problems
- • Enrolment of the investigator, his/her family members, employees and other dependent persons
About Insel Gruppe Ag, University Hospital Bern
Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bern, , Switzerland
Patients applied
Trial Officials
Regula Everts, Prof. Dr.
Principal Investigator
Division of Neuropaediatrics, Development and Rehabilitation, Department of Paediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported